Biohaven's orally dissolving tablet meets in Phase III for acute migraine

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) added $8.66 (25%) to $42.65 on Monday after reporting that its orally dissolving tablet (ODT) formulation of rimegepant met the co-primary endpoints in the Phase III BHV3000-303 trial for the acute treatment of migraine. The company updated its timeline from 2019 and now plans to submit NDAs to FDA in 1H19 for the calcitonin-gene related peptide (CGRP) receptor antagonist.

Biohaven reported in March that a once-daily oral tablet formulation of rimegepant met the co-primary endpoints in the Phase III 301 and 302 trials for acute migraine (see "Biohaven's Acute Migraine Candidate Meets in Phase III")...